NCT04863131View on ClinicalTrials.gov

Safety and Immunogenicity of EXG-5003

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 28, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

January 24, 2023

Conditions
COVID-19
Interventions
BIOLOGICAL

EXG-5003

COVID-19 self-replicating mRNA vaccine

BIOLOGICAL

Placebo

placebo solution

Trial Locations (1)

Unknown

Fujita Health University Hospital, Toyoake

Sponsors
All Listed Sponsors
collaborator

Elixirgen Therapeutics, Inc.

INDUSTRY

lead

Fujita Health University

OTHER